Open AccessTime to Loss of Response following Withdrawal of Ixekizumab in Patients with Moderate-to-Severe Psoriasis
Author(s) -
Kim Papp,
Carle Paul,
Elise Kleyn,
YuHuei Huang,
TsenFang Tsai,
Christopher Schuster,
Céline El Baou,
A. Tóth,
Elisabeth Riedl,
Ulrich Mrowietz
Publication year - 2022
Publication title -
acta dermato-venereologica
Language(s) - English
Resource type - Journals
eISSN - 1651-2057
pISSN - 0001-5555
DOI - 10.2340/actadv.v102.1984
Subject(s) - ixekizumab , medicine , confidence interval , psoriasis , placebo , post hoc analysis , randomized controlled trial , clinical trial , psoriasis area and severity index , dermatology , alternative medicine , pathology , secukinumab , psoriatic arthritis
In clinical practice, interruption of treatment may not result in immediate cessation of disease control, and some patients even experience sustained treatment response following treatment interruption. This post hoc analysis of UNCOVER-1 and -2 Phase 3 clinical trials characterized the time to loss of treatment response in patients with psoriasis who responded to ixekizumab through a 12-week treatment period, and who were then re-randomized to placebo for the following 48 weeks. For those with static Physician Global Assessment [sPGA]0/1 and Psoriasis Area and Severity Index [PASI]90 at Week 12, the median time to loss of PASI90 was 16.1 weeks (95% confidence interval 12.7–16.4). For those with PASI100 at Week 12, the median time to loss of PASI100 was 12.1 weeks (95% confidence interval 9.0–13.0). A small subset of patients maintained high levels of disease control through Week 60. This study adds to the growing body of evidence on sustained treatment response following treatment interruption.